Cerebroprotein Hydrolysate for Health & Longevity

Evidence Review created on 10/29/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Cerebrolysin, Renacenz, FPF-1070, Cerebroprotein Hydrolysate-I, CH-I, Cognistar

Motivation

Cerebroprotein hydrolysate, best known by the brand name Cerebrolysin, is a prescription injection made by breaking down purified pig brain proteins into small protein fragments and free amino acids. It is given as a course of daily infusions into a vein or injections into a muscle. Its appeal for people focused on long-term brain health is the idea that these fragments act like the brain’s own growth-support signals, which help nerve cells survive and form new connections.

The preparation has been used for decades across Europe and Asia for stroke, head injury and dementia, yet it is not approved in the United States. More recently it has drawn interest from longevity clinics and self-experimenters as a possible way to protect memory and slow brain aging, often obtained through informal supply channels.

This review examines what human trials, pooled analyses, animal studies and product labels show about its benefits, harms, dosing and sourcing, with a focus on healthy, risk-aware adults weighing its use for brain health and longevity.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that discuss cerebroprotein hydrolysate in depth.

  • Cerebrolysin & Your Brain - Alzheimer’s Drug Discovery Foundation

    Rating from the Alzheimer’s Drug Discovery Foundation (ADDF), a nonprofit with no reported stake in the product: no dementia-prevention or cognition studies in healthy adults, modest effects in dementia trials, contamination risk and oral inactivity.

  • Cerebrolysin: a review of its use in dementia - Plosker & Gauthier, 2009

    Narrative drug review of the randomized Alzheimer’s and vascular dementia (dementia from reduced brain blood flow) trials, dosing schedules and tolerability; co-author Gauthier led manufacturer-supported Cerebrolysin trials.

  • Cerebrolysin: a multi-target drug for recovery after stroke - Brainin, 2018

    Stroke-focused narrative review arguing that benefit grows with stroke severity and with added rehabilitation; Brainin co-authored manufacturer-supported stroke trials.

Only three items are listed: the other candidates were laboratory studies, systematic reviews, commercial vendor guides or brief podcast mentions rather than high-level overviews.

No directly relevant content was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io: web searches and each platform’s own search returned no article, episode or post discussing Cerebrolysin or cerebroprotein hydrolysate. Andrew Huberman’s platform has only a brief exchange on Cerebrolysin in an episode with physician Craig Koniver, too short for an overview; it is cited under Therapeutic Protocol.

Grokipedia

Cerebrolysin

AI-written encyclopedia entry covering composition, dosing, stroke, dementia and brain-injury evidence, safety and regulatory status; its overview dates the product to the 1970s while its own history section gives 1949.

Examine

No Examine article on cerebroprotein hydrolysate or Cerebrolysin exists. Examine.com does not typically cover prescription medications, and Cerebrolysin is a prescription injection in the countries where it is approved.

ConsumerLab

No ConsumerLab article on cerebroprotein hydrolysate or Cerebrolysin exists. ConsumerLab does not typically cover prescription medications, and Cerebrolysin is a prescription injection rather than a dietary supplement.

Systematic Reviews

These systematic reviews and meta-analyses cover efficacy and harms in stroke, dementia and brain injury.

Mechanism of Action

Cerebroprotein hydrolysate is made by enzymatic digestion of purified pig brain protein. Cerebrolysin, the reference product, is described as about 25% low-molecular-weight peptides and 75% free amino acids (Florek 2025); one trial report gives 15% and 85% (Allam 2018). The manufacturer, EVER Neuro Pharma, and its collaborators propose that the peptides mimic neurotrophic factors (proteins such as BDNF, brain-derived neurotrophic factor, and NGF, nerve growth factor, that keep nerve cells alive and connected):

  • New nerve cells: in rats after stroke, it increased neuron and myelin-cell formation through the Sonic hedgehog pathway (a developmental growth-signaling route); blocking the pathway abolished the benefit (Zhang 2013).
  • Amyloid processing: in Alzheimer’s-model mice, it lowered amyloid-beta production by reducing CDK5 and GSK-3β activity (enzymes that phosphorylate the amyloid precursor protein) (Rockenstein 2006); several later papers from that laboratory were retracted (Rockenstein 2025).
  • Growth-factor receptors: in aged rats, it restored cortical TrkA (the receptor for NGF) (Stepanichev 2017).

Pharmacology: the label states that conventional pharmacokinetics (how the body absorbs, distributes and clears a drug) cannot be measured for the mixture (Russian Cerebrolysin label (Vidal)), so half-life, selectivity and brain penetration are uncharacterized. In a maker-co-authored rat study, a Chinese hydrolysate’s peptides appeared only briefly in blood (Zhang 2024). Breakdown into amino acids is presumed; no CYP (liver drug-metabolizing enzyme) pathway is described.

Competing view: look-alike hydrolysates lacked nerve-growth activity in cell assays (Seidl 2024), and the label’s claim that the peptides cross the blood-brain barrier lacks human confirmation.

Historical Context & Evolution

Cerebrolysin was developed in Innsbruck, Austria, in 1949 and became most popular in Eastern Europe; it is used in dozens of countries but is not registered in the United States (Florek 2025). Its intended use is treating brain disease: the Austrian label lists Alzheimer’s-type dementia, vascular dementia, stroke and head trauma (EVER prescribing information), and the Russian label adds chronic cerebrovascular insufficiency (reduced brain blood flow), treatment-resistant depression and childhood developmental indications (Russian Cerebrolysin label (Vidal)).

From the 1990s, manufacturer-supported trials in Alzheimer’s disease reported small cognitive and global gains (Ruether 2001). In stroke, the large manufacturer-sponsored CASTA trial was neutral (Heiss 2012), while the manufacturer-co-authored CARS rehabilitation trials were positive (Muresanu 2016). Independent Cochrane reviews have consistently found no survival benefit, and the 2023 update reports more non-fatal serious adverse events (Ziganshina 2023). The European Academy of Neurology and European Federation of Neurorehabilitation Societies nevertheless recommended it for early motor rehabilitation (Beghi 2021); the guideline panel included the lead investigator and the statistician of those trials, while the society’s neurologist members earn no procedure-based revenue from the drug. In 2019, China’s National Health Commission (NHC) placed cerebroprotein hydrolysate on its first national list of drugs under key monitoring for rational use, tied to public-hospital performance reviews (NHC notice (gov.cn)); state funding of hospitals may add budget motives to such restrictions.

Interest for health optimization grew from aged-rodent studies, peptide-clinic use and small oral-derivative trials in healthy older adults; whether animal findings translate to healthy people remains open.

Expected Benefits

High 🟩 🟩 🟩

Early Neurological and Motor Recovery After Ischemic Stroke ⚠️ Conflicted

Infusions within 72 hours of ischemic stroke improved NIHSS (National Institutes of Health Stroke Scale, a standardized neurological examination) scores in a meta-analysis of manufacturer-supported Muresanu–Vester consortium trials (Bornstein 2018) and an independent Kazan group trial (Khasanova 2023), and in a 14-trial pooled analysis (Patel 2025); arm function improved with rehabilitation in a manufacturer-co-authored trial (Muresanu 2016). The largest trial (1,070 patients) missed its primary endpoint (Heiss 2012), and independent pooled analyses found no 90-day disability benefit (Wang 2017). Net: early deficit scores improve modestly; durable independence gains remain unproven.

Magnitude: NIHSS improved 1.39 points more than with placebo, 95% CI (confidence interval, the range likely to contain the true effect) 0.53 to 2.25, across the six trials (1,521 patients) that reported NIHSS change, although the abstract implies all 14; functional independence was 49.9% versus 45.7% with placebo, a non-significant RR (risk ratio, the ratio of event rates between groups) of 1.31 (95% CI 0.90 to 1.91) (Patel 2025).

Short-Term Cognitive Improvement ⚠️ Conflicted

Infusion courses improved cognition or global ratings in mostly manufacturer-supported Alzheimer’s trials from Germany (Ruether 2001), Korea (Bae 2000), Canada (Panisset 2002) and Spain (Alvarez 2006), and, per two meta-analyses, in vascular cognitive decline (Cui 2019; Masserini 2025). A manufacturer-co-authored open-label (unblinded) comparison slowed mild cognitive impairment (pre-dementia decline) (Gavrilova 2010). Manufacturer-linked healthy-adult studies show only a non-significant memory trend (Funke 1998) and indirect oral-derivative data (Chira 2026). Independent pooling found effects probably below clinical relevance (Alsulaimani 2021). Net: small short-term gains in impaired brains; unproven in healthy ones.

Magnitude: Cognition SMD (standardized mean difference, effect size in standard-deviation units) −0.16 (95% CI −0.30 to −0.03; 8 trials, 793 participants; negative favors treatment) and global function OR (odds ratio, the ratio of the odds of improvement between groups) 2.64 (95% CI 1.17 to 5.98) versus placebo (Alsulaimani 2021).

Neurological Recovery in Degenerative Cervical Myelopathy

In degenerative cervical myelopathy (spinal-cord compression from age-related changes in the neck spine), four weeks of Cerebrolysin plus celecoxib (an anti-inflammatory drug) improved Japanese Orthopaedic Association scores (a spinal-cord function scale) more than placebo plus celecoxib in 192 non-operated patients in Egypt (Allam 2018), and ten postoperative days improved one-year scores in 90 surgical patients in India (Sharma 2023). Both trials were single-country and modest in size.

Magnitude: In surgical patients, the modified Japanese Orthopaedic Association score was 1.17 points higher than with placebo at one year (16.37 versus 15.2) (Sharma 2023); in non-operated patients, 87% versus 33% had improved at six months (Allam 2018).

Medium 🟩 🟩

Functional Recovery After Moderate-to-Severe Traumatic Brain Injury

In the manufacturer-sponsored CAPTAIN program, led from Hong Kong (Poon 2020) and Romania (Muresanu 2020) by one research consortium, 50 mL daily for ten days plus two 10 mL cycles improved a composite of 13 to 14 outcome scales; the first trial narrowly missed significance in its main analysis. Pooled analyses dominated by cohort studies report better Glasgow Outcome Scale (a five-level recovery rating) scores without a change in mortality (Jarosz 2023).

Magnitude: Pooled CAPTAIN day-90 MW (Mann–Whitney estimator, the probability that a treated patient fares better than a placebo patient; 0.50 means no difference) 0.60 (95% CI 0.52 to 0.68; 185 patients), SMD 0.34 (Vester 2021).

Language Recovery in Post-Stroke Aphasia

In one aphasia (loss of language ability after brain injury) trial at two Romanian centers with 123 patients analyzed, three 10-day Cerebrolysin cycles added to speech therapy improved language scores and neurological deficits more than placebo plus speech therapy (Homberg 2025). The investigators belong to the network that ran the manufacturer-supported stroke trials, and no independent replication exists.

Magnitude: The Western Aphasia Battery (a standardized language test) rose 14.8 points more than with placebo at day 90 (95% CI 9.5 to 20.1) (Homberg 2025).

Fewer Symptomatic Brain Hemorrhages After Reperfusion Therapy

Reperfusion therapy (clot-dissolving drugs or mechanical clot removal) can cause bleeding into the damaged brain area. In an open-label Kazan trial, Cerebrolysin given with alteplase (a clot-dissolving drug) lowered symptomatic bleeding versus alteplase alone (Khasanova 2023). A pooled analysis of three observational clot-removal studies found fewer symptomatic hemorrhages (Afridi 2026), and a 14-trial pooled analysis reported hemorrhagic transformation RR 0.55 (95% CI 0.32 to 0.92), which its abstract nonetheless calls non-significant (Patel 2025). No placebo-controlled trial has tested this as its main outcome.

Magnitude: Symptomatic bleeding OR 0.25 (95% CI 0.07 to 0.85) with Cerebrolysin plus alteplase (126 patients) versus alteplase alone (215 patients); not placebo-controlled (Khasanova 2023).

Recovery of Smell and Taste After Coronavirus Infection

In an Egyptian trial of 250 adults with persistent smell loss after COVID-19 (coronavirus disease 2019), intramuscular Cerebrolysin (5 mL, five days weekly) plus smell and taste training was compared with training alone (Hamed 2023). Complete recovery occurred only with Cerebrolysin. The control group received no placebo injection, allocation was unequal, and 202 patients were analyzed.

Magnitude: Complete recovery in 61.5% (80 of 130) with Cerebrolysin plus training versus no recovery among 72 analyzed with training alone; not placebo-controlled (Hamed 2023).

Low 🟩

Survival After Acute Stroke or Brain Hemorrhage ⚠️ Conflicted

A post hoc (after-the-fact) severe-stroke subgroup had lower 90-day mortality (Heiss 2012), and a subarachnoid hemorrhage (bleeding around the brain) meta-analysis suggested lower mortality (Kojder 2023). Cochrane found no effect on death (Ziganshina 2023). Net: no survival benefit is established.

Magnitude: All-cause death in 53 of 922 with Cerebrolysin or Cortexin versus 47 of 767 with placebo or no treatment, RR 0.96 (95% CI 0.65 to 1.41; 6 trials, 1,689 participants) (Ziganshina 2023).

Adjunct Treatment of Antidepressant-Resistant Depression

The Russian label lists antidepressant-resistant depression as an add-on indication (Russian Cerebrolysin label (Vidal)). A scoping review found only uncontrolled reports and conference abstracts supporting this use (Florek 2025).

Magnitude: Not quantified in available studies. No controlled trial has measured mood outcomes; only uncontrolled reports and conference abstracts exist.

Developmental Delay in Children ⭕️ Not Central to Health & Longevity

This bears on child neurodevelopment, not adult longevity. The Russian label lists childhood developmental delay (Russian Cerebrolysin label (Vidal)). In 102 Chinese children under three, intravenous hydrolysate-I then oral derivatives (a route and form mismatch) added to rehabilitation improved fine-motor and adaptive skills; the maker co-authored it (Hua 2025).

Magnitude: Developmental efficacy rate at 90 days was 87.2% (41 of 47) with the hydrolysate plus rehabilitation versus 54.5% (24 of 44) with rehabilitation alone; not placebo-controlled (Hua 2025).

Attention-Deficit/Hyperactivity in Children ⭕️ Not Central to Health & Longevity

This bears on childhood attention and behavior, not adult longevity. The Russian label lists childhood attention-deficit/hyperactivity disorder (Russian Cerebrolysin label (Vidal)). In an uncontrolled Russian study, one month of intramuscular injections was followed by normalized neurological and immune findings (Sotnikova 2002).

Magnitude: Direction favors normalization of neurological findings after one month, no control group; the literature reports no outcome figure (Sotnikova 2002).

Speculative 🟨

In aged mice, chronic treatment increased dendritic spines (tiny contact points between nerve cells) and BDNF (Aguilar-Hernández 2025); in aged rats, memory effects were minor (Stepanichev 2017). The basis is animal data only.

Lower Amyloid and Tau Pathology

Alzheimer’s-model mice showed less amyloid (Rockenstein 2006); in patients, tau fell only in plasma vesicles, an unvalidated biomarker, in a manufacturer-co-authored trial (Alvarez 2022). The basis is mechanistic.

Longer Lifespan and Slower Epigenetic Aging

In mice with CADASIL (an inherited small-vessel brain disease), a nine-week course extended lifespan and reduced epigenetic aging (age estimated from DNA chemical marks) (Kastberger 2024); manufacturer staff co-authored it. No human data exist.

Benefit-Modifying Factors

  • Genetic polymorphisms (APOE4, an Alzheimer’s-risk form of a cholesterol-transport gene): carriers responded less in a Russian Alzheimer’s comparison (Gavrilova 2005) but more in mild cognitive impairment (Gavrilova 2010), and showed larger serum BDNF rises in a manufacturer-co-authored combination-therapy trial (Alvarez 2016); findings conflict.
  • Baseline severity: larger stroke benefits appeared with more severe deficits: a non-significant post hoc trend above NIHSS 12 (Heiss 2012) and a significant gain only in severe motor impairment (Chang 2016); mildly affected people have little room to improve.
  • Baseline biomarkers: no biomarker predicts response; serum BDNF rose with treatment in Alzheimer’s patients (Alvarez 2016) but is not validated for selecting candidates.
  • Sex: no sex-specific efficacy analyses have been reported in human trials, so any difference between women and men is unknown.
  • Pre-existing conditions: all injected-product evidence comes from people with stroke, dementia, brain injury or spinal-cord disease; in healthy brains, only a small injected-product trial (Funke 1998) and indirect, manufacturer-co-authored oral-derivative data exist (Crook 2005).
  • Age: dementia trials enrolled older adults; in aged rats, receptor changes occurred with minimal memory benefit (Stepanichev 2017), so older age alone does not predict benefit.
  • Dose: response followed an inverted U: 10 mL improved cognition while 30 and 60 mL did not, although all doses improved global ratings (Alvarez 2006).
  • Concurrent rehabilitation: motor and language gains were shown only with structured rehabilitation or speech therapy (Muresanu 2016; Homberg 2025).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no harm has been shown in placebo-controlled trials from more than one independent research group; the evidence consists of conflicting pooled stroke analyses, product labels and case reports.

Medium 🟥 🟥

No risk reaches Medium: the only placebo-controlled harm signal, non-fatal serious events in stroke trials, is outweighed by a larger pooled analysis of randomized trials, and other harms rest on product labels and case reports.

Low 🟥

Non-Fatal Serious Adverse Events in Acute Stroke ⚠️ Conflicted

Cochrane found more non-fatal serious events with Cerebrolysin in three placebo-controlled stroke trials, at moderate certainty (Ziganshina 2023). A larger 12-trial pooled analysis by manufacturer-trial investigators found no significant excess (Strilciuc 2021). Net: the larger analysis does not confirm the signal.

Magnitude: Non-fatal serious events in 20 of 667 with Cerebrolysin versus 8 of 668 with placebo, RR 2.39 (95% CI 1.10 to 5.23; 3 trials, 1,335 participants) (Ziganshina 2023); in the larger analysis, 3.8% with Cerebrolysin versus 3.0% with placebo, RR 1.18 (95% CI 0.75 to 1.86; 12 trials, 2,156 patients) (Strilciuc 2021).

Infusion-Rate and Injection-Site Reactions ⚠️ Conflicted

Rapid injection can cause dizziness, heat, sweating, palpitations and, very rarely, arrhythmia; injection-site redness or burning is very rare (Russian Cerebrolysin label (Vidal)). 50 mL in healthy volunteers caused mild overdose signs (Funke 1998). A manufacturer-co-authored review found placebo-level adverse-event rates (Thome 2012). Net: mild, rate-dependent.

Magnitude: The label rates dizziness after rapid injection as rare (1 in 10,000 to 1 in 1,000) and gives no comparison-group rate (Russian Cerebrolysin label (Vidal)).

Central Nervous System Activation and Low Mood ⚠️ Conflicted

The label lists rare agitation, confusion and insomnia, possible low mood or apathy and very rare seizures (Russian Cerebrolysin label (Vidal)); agitation ranks among common trial events in a safety review (Thome 2012). The label notes agitation and depression occurred equally with placebo in trials. Net: uncommon and transient.

Magnitude: The label rates agitation, confusion and insomnia as rare (1 in 10,000 to 1 in 1,000) and gives no comparison-group rate (Russian Cerebrolysin label (Vidal)).

Anaphylaxis and Hypersensitivity

The label lists very rare hypersensitivity reactions, with skin reactions, head, neck, limb and back pain, fever, breathlessness, chills and collapse (Russian Cerebrolysin label (Vidal)). A laboratory-confirmed, life-threatening anaphylaxis (a severe, rapid allergic reaction) followed infusion in an 85-year-old (Trimmel 2024).

Magnitude: The label rates hypersensitivity as very rare (under 1 in 10,000) and gives no comparison-group rate; published human data are case reports without a control group, and the authors of one such report count 35 earlier Chinese cases of anaphylaxis from 1994 to 2009, one fatal (Trimmel 2024).

Gastrointestinal Upset and Appetite Loss ⚠️ Conflicted

The label lists very rare nausea, vomiting, diarrhea, constipation and indigestion, and rare appetite loss, noting nausea and diarrhea occurred equally with placebo (Russian Cerebrolysin label (Vidal)). Weight loss was common in an Alzheimer’s trial with fewer overall adverse events than placebo (Panisset 2002). Net: rare, not shown above placebo.

Magnitude: The label rates nausea, vomiting, diarrhea, constipation and indigestion as very rare (under 1 in 10,000) and appetite loss as rare (1 in 10,000 to 1 in 1,000), and gives no comparison-group rate (Russian Cerebrolysin label (Vidal)).

Headache ⚠️ Conflicted

Headache was among the most common adverse events in an Alzheimer’s trial in which overall adverse events were fewer than with placebo (Panisset 2002). The label notes headache occurred equally with placebo in trials (Russian Cerebrolysin label (Vidal)). Net: common but not shown in excess of placebo.

Magnitude: Adverse events of any kind occurred in 64% with Cerebrolysin versus 73% with placebo; the trial reported no separate headache rates (Panisset 2002).

Blood-Pressure Changes and Other Rare Reactions ⚠️ Conflicted

The label lists rare blood-pressure changes, rapid breathing, fatigue, tremor, drowsiness and flu-like symptoms (Russian Cerebrolysin label (Vidal)). 50 mL slightly lowered blood pressure in healthy volunteers (Funke 1998), but a safety review found no major vital-sign changes (Thome 2012). Net: rare and minor.

Magnitude: The label rates these reactions as rare (1 in 10,000 to 1 in 1,000) and gives no comparison-group rate (Russian Cerebrolysin label (Vidal)).

Speculative 🟨

Contamination From Animal Tissue or Unregulated Vials

Pig-brain origin carries a theoretical bacterial, viral or fungal contamination risk (ADDF rating; ADDF is a nonprofit with no reported stake); unregulated vials lack sterility assurance. No transmitted infection is reported; the basis is theoretical.

Growth Signaling in Existing Tumors

Growth-factor-like signaling could in theory support existing tumors. No human or animal study has tested this; the concern is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: no gene variant is known to alter harms; with no CYP metabolism described, common drug-metabolism variants are not expected to matter.
  • Baseline kidney function: severe kidney impairment is a label contraindication (Russian Cerebrolysin label (Vidal)), making baseline creatinine the key laboratory factor.
  • Sex: no sex differences in adverse events have been reported; pregnancy and breastfeeding lack clinical data, and the label restricts use to careful benefit-risk review (Russian Cerebrolysin label (Vidal)).
  • Pre-existing conditions: epilepsy (possible increase in seizure frequency) and allergic tendencies, both label cautions (Russian Cerebrolysin label (Vidal)), and acute stroke, where the non-fatal serious event signal arose (Ziganshina 2023), raise risk.
  • Age: the anaphylaxis case involved an 85-year-old (Trimmel 2024); the label notes many complaints in elderly users occur at similar rates without the drug.
  • Dose and infusion rate: fast injection causes heat, sweating and dizziness (Russian Cerebrolysin label (Vidal)); 50 mL in healthy volunteers caused mild overdose signs and a small blood-pressure fall (Funke 1998).
  • Product source: look-alike preparations differed in composition and lacked activity in laboratory tests (Seidl 2024), and gray-market vials add sterility uncertainty absent from registered ampoules.

Key Interactions & Contraindications

Documented interactions:

  • Antidepressants (sertraline, escitalopram, amitriptyline): the label warns of additive effects and advises lowering the antidepressant dose (Russian Cerebrolysin label (Vidal)); consequence: excess antidepressant or activating effects. Mitigation: dose review before a course.
  • MAOIs (monoamine oxidase inhibitors, drugs that block breakdown of brain messengers, used for depression or Parkinson’s disease: phenelzine, tranylcypromine, selegiline, rasagiline): 30–40 mL with high-dose MAOIs may raise blood pressure (Russian Cerebrolysin label (Vidal)). Avoid (high-dose combination); mitigation: blood-pressure monitoring.
  • Alteplase (clot-dissolving drug): no interaction found; combined treatment was safe (Lang 2013), and symptomatic bleeding into the infarct (the area of dead brain tissue) was less frequent, OR 0.25 (Khasanova 2023).
  • Cholinesterase inhibitors (Alzheimer’s drugs that raise the memory messenger acetylcholine: donepezil, rivastigmine): no interaction found; combinations were safe in a manufacturer-co-authored trial (Alvarez 2011) and a safety review (Thome 2012).
  • Infusion fluids (balanced amino-acid solutions, lipid emulsions, solutions outside pH 5.0–8.0): physically incompatible; consequence: product degradation. Avoid (mixing in one infusion); vitamins and cardiovascular drugs can be given separately (Russian Cerebrolysin label (Vidal)).
  • Rehabilitation and speech therapy: additive; motor and language gains appeared only when combined with structured therapy (Muresanu 2016; Homberg 2025).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Over-the-counter stimulants and decongestants (caffeine tablets, pseudoephedrine, phenylephrine): inferred from additive nervous-system activation and blood-pressure effects; consequence: insomnia, agitation, blood-pressure rise. Mitigation: separation from infusion days.
  • Serotonergic supplements (supplements that raise brain serotonin: St John’s wort, 5-HTP, a serotonin precursor, and SAMe, S-adenosylmethionine): inferred from the label’s additive antidepressant effect; consequence: agitation, insomnia or excess serotonergic activity. Mitigation: a pause during each course.
  • Other brain-peptide products (N-PEP-12, Cortexin, Actovegin): inferred from overlapping neurotrophic activity; consequence: duplicated exposure with unknown cumulative effects. Mitigation: one product at a time.

Populations who should avoid Cerebroprotein Hydrolysate:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Registered product only: registered Cerebrolysin ampoules, rather than gray-market vials, avoid unverified sterility and substitution with look-alikes, which lacked activity in laboratory tests (Seidl 2024).
  • Slow, diluted infusion: 10–50 mL diluted to at least 100 mL (EVER dosing guide) and infused over 15–60 minutes (Russian Cerebrolysin label (Vidal)) prevents rate-related dizziness, heat, sweating and palpitations.
  • Supervised first dose: a first infusion given where epinephrine is available, with observation afterward, mitigates anaphylaxis, which in reported cases began minutes to hours after infusion, most often after the first dose (Trimmel 2024).
  • Kidney screen: creatinine and eGFR measured before each course identify severe renal impairment, the label contraindication (EVER prescribing information).
  • Seizure history screen: screening for epilepsy before a first course prevents the label-described seizure provocation (Russian Cerebrolysin label (Vidal)).
  • Antidepressant review: a lower antidepressant dose, as the label advises, and no 30–40 mL doses with high-dose MAOIs prevent activation and blood-pressure rise (Russian Cerebrolysin label (Vidal)).
  • Morning dosing and mood check: morning infusions, with a pause if agitation, insomnia or low mood lasts beyond two days, limit nervous-system activation.
  • Aseptic handling: single use of each ampoule, immediately after opening, only if clear, with storage at 25 °C or below away from light, prevents contamination (Russian Cerebrolysin label (Vidal)).

Therapeutic Protocol

Other parameters without a citation, such as timing, cycling and titration steps, reflect common practice.

  • Manufacturer regimen for cognitive problems: 10–30 mL daily by vein, five days weekly for four weeks, two to four cycles yearly (EVER dosing guide).
  • Dementia trial regimen: 30 mL in 100 mL saline, five days weekly for four weeks, repeated after two months (Ruether 2001); 10 mL gave the best cognitive response in dose-finding (Alvarez 2006).
  • Stroke regimens: 30 mL daily for 21 days with rehabilitation (Muresanu 2016), or at least 10 days per the European neurology societies’ guideline, whose neurologist members earn no revenue from the drug (Beghi 2021).
  • Brain-injury regimen: 50 mL daily for 10 days, then two 10 mL cycles (Vester 2021).
  • Practitioner approach: physician Craig Koniver used intravenous and subcutaneous Cerebrolysin in his London and Charleston clinics, then largely stopped because of transient low mood (Huberman Lab episode).
  • Intramuscular option: up to 5 mL undiluted, injected slowly over three minutes (EVER dosing guide); 5 mL five days weekly was used for post-COVID smell loss (Hamed 2023).
  • Oral derivative: N-PEP-12 at 45 or 90 mg daily in healthy adults aged 50–75 (Chira 2026); oral Cerebrolysin itself is broken down in the gut (ADDF rating; nonprofit, no stake in the product).
  • Chinese hydrolysates: dosed by product-specific labels; not interchangeable with Cerebrolysin milliliter doses because composition and activity differ (Seidl 2024).
  • Time of day: morning or early-afternoon infusions limit the label-listed insomnia (Russian Cerebrolysin label (Vidal)).
  • Half-life: not measurable for the mixture; rat data suggest brief peptide exposure (Zhang 2024), while clinical effects persisted three months after courses (Ruether 2001).
  • Single versus split dosing: one daily infusion; no study has tested split dosing.
  • Genetic polymorphisms: APOE4 status has conflicting response data (Gavrilova 2005; Alvarez 2016) and no basis for dose changes.
  • Sex: trials enrolled women and men without sex-stratified dosing or results; no sex-specific protocol exists.
  • Age: older-adult dementia trials used standard doses; slower infusion and antidepressant review matter more in older users.
  • Baseline biomarkers: baseline cognitive scores and stroke severity defined trial populations; no biomarker guides dose.
  • Pre-existing conditions: severe renal impairment and epilepsy exclude use (EVER prescribing information); stroke and spinal-cord protocols pair infusions with rehabilitation.

Discontinuation & Cycling

  • Course-based, not lifelong: courses last 10–20 days, with repeat courses every three to six months for chronic conditions per the label (Russian Cerebrolysin label (Vidal)).
  • Withdrawal effects: none reported; dementia benefits persisted three months after stopping in manufacturer-co-authored trials (Ruether 2001; Muresanu 2010).
  • Tapering: not applicable; trial courses ended without tapering.
  • Cycling: cycling is built into labeled regimens, two to four courses yearly (EVER dosing guide); no trial compared cyclic with continuous use.
  • Stopping a course early: courses are stopped for hypersensitivity, seizures, or persistent agitation or low mood.

Sourcing and Quality

  • Reference product: Cerebrolysin from EVER Neuro Pharma, Austria, 215.2 mg/mL concentrate in ampoules, prescription-only (EVER prescribing information).
  • Non-equivalent hydrolysates: Cognistar, Cerebrolysat and Cortexin gave no functional benefit in rat stroke while Cerebrolysin did (Zhang 2019), and look-alikes differed in composition (Seidl 2024); both used Cerebrolysin as reference.
  • Chinese cerebroprotein hydrolysates: sold by many manufacturers and placed on a national key-monitoring list in 2019 (NHC notice (gov.cn)); composition varies by maker.
  • Gray-market “research” vials: no regulatory oversight, so identity, concentration and sterility are unverified; contamination is the main concern (ADDF rating; nonprofit, no stake in the product).
  • What to look for: pharmacy-dispensed sealed ampoules with batch number and expiry; a clear, yellowish-brown solution; storage at 25 °C or below, protected from light (Russian Cerebrolysin label (Vidal)).
  • Third-party testing: no independent supplement-testing program covers this prescription injection; regulated pharmacy supply is the quality safeguard.

Practical Considerations

  • Time to effect: cognitive changes appeared after four weeks in a dementia meta-analysis (Gauthier 2015) and neurological changes within 14 to 21 days after stroke in a CARS meta-analysis (Guekht 2017), both manufacturer-co-authored; oral N-PEP-12 effects appeared at 30 to 90 days (Chira 2026).
  • Common pitfalls: assuming oral or nasal use matches infusion, injecting too fast, mixing with amino-acid solutions, substituting look-alike products, and extrapolating dementia results to healthy brains.
  • Regulatory status in the United States: not registered with the US Food and Drug Administration and not approved for sale or distribution (EVER prescribing information).
  • Regulatory status elsewhere: prescription-only in Austria for dementia, stroke and head trauma (EVER prescribing information) and in Russia with broader indications (Russian Cerebrolysin label (Vidal)); China monitors hospital use (NHC notice (gov.cn)).
  • Access: a standard course means about 20 clinic infusions; outside approving countries, access usually requires travel or informal supply.

Interaction with Foundational Habits

  • Sleep: direction direct, possibly disruptive; the label lists rare insomnia as part of an activating effect (Russian Cerebrolysin label (Vidal)). Morning infusions avoid bedtime overlap; no study has measured sleep quality.
  • Nutrition: direction none known; the product is injected, so meals do not affect absorption, and its amino-acid content is small relative to dietary protein (inferred). Doses of 19 mL or more add over 1 mmol sodium (Russian Cerebrolysin label (Vidal)).
  • Exercise: direction potentiating in rehabilitation; motor gains after stroke appeared when infusions accompanied a standardized 21-day rehabilitation program (Muresanu 2016). No data exist for healthy exercisers or performance outcomes.
  • Stress management: direction indirect; possible transient low mood or agitation (Russian Cerebrolysin label (Vidal)) can affect stress resilience during a course, and the label notes additive effects with antidepressants. No cortisol data exist.

Monitoring Protocol & Defining Success

Before a first course, baseline testing establishes safety and a reference point: serum creatinine with eGFR to exclude severe renal impairment, seated blood pressure, a standardized cognitive test, and optionally serum BDNF, so that later change can be measured against the individual’s own starting values.

Ongoing monitoring follows the course cadence: blood pressure at the first infusion and then weekly during each four-week course; cognitive testing at the end of each course and again three months later, matching trial timepoints; and creatinine before every subsequent course, typically every three to six months. Success means a measurable cognitive gain over baseline without adverse events, judged against the small effects seen in trials.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine with eGFR 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women (standard reference range) Safety check: severe renal impairment stops use Label gives no eGFR cutoff (Russian Cerebrolysin label (Vidal)); eGFR is calculated from creatinine, age and sex; no fasting needed; laboratory ranges vary slightly
Blood pressure Below 120/80 mmHg, the normal category in the ACC/AHA 2017 guideline Safety check: rapid infusion and MAOI combinations shift pressure ACC/AHA: American College of Cardiology/American Heart Association, professional societies whose clinician members treat high blood pressure but earn no revenue tied to Cerebrolysin (Whelton 2018); conventional reference range is the same below-120/80 threshold; seated readings after five minutes’ rest, before and after infusion
Cognitive score (MoCA) No established target; change from the individual’s own baseline is tracked Marker expected to change: trials measured cognitive scores MoCA: Montreal Cognitive Assessment, a 30-point screening test; alternate versions limit practice effects; testing at the same time of day improves comparability
Serum BDNF No established target; change from the individual’s own baseline is tracked Marker expected to change: rose with Cerebrolysin in Alzheimer’s patients (Alvarez 2016) Research assay; serum and plasma values differ; the same laboratory and draw time keep results comparable

Qualitative markers:

  • Mental clarity, word-finding and recall in daily tasks
  • Mood stability, especially low mood or irritability in the days after infusions
  • Sleep onset and quality on infusion days
  • Energy and fatigue
  • Dizziness, flushing or headache during or after infusions
  • Injection-site redness, burning or swelling

Emerging Research

  • CADASIL crossover trial: NCT05755997, manufacturer-sponsored phase 2 trial in 30 patients with CADASIL, measuring a cognitive battery and white-matter lesion volume; active, not recruiting, completion December 2026. A positive result would give the first human support for the mouse aging data; a null result would weaken it.
  • Extended-window thrombectomy: NCT06339411, Chang Gung multicenter phase 2 trial of infusions after thrombectomy (mechanical clot removal) in 100 patients, primary endpoint final infarct volume; not yet recruiting, completion 2030. A positive result would support brain protection after clot removal; a null result would narrow stroke use further.
  • Early stroke rehabilitation: NCT07043686, Ljubljana study in 30 patients, primary endpoint 90-day arm function; recruiting, completion 2027. A positive result would independently replicate the motor findings; a null result would weaken the stroke-recovery item.
  • Independent aphasia trial: NCT06897176, Yonsei University phase 4 placebo-controlled trial adding Cerebrolysin to speech therapy in 40 patients with non-fluent aphasia after stroke, primary endpoint Korean Western Aphasia Battery; recruiting, completion December 2027. A positive result would give the aphasia item its first independent replication; a null result would weaken it.
  • Blood-brain barrier study (CERBERUS): NCT06078215, Poznan trial in 350 patients; registered completion March 2025 has passed, status unknown, no results posted.
  • Delirium in critical illness: NCT06677502, Lublin study in 500 patients; registered completion December 2025 has passed, listed as enrolling by invitation, no results posted.
  • Healthy-aging gap: no registered trial tests the injected product in healthy adults; the oral N-PEP-12 trial (Chira 2026) needs independent replication, which could strengthen or weaken the only healthy-aging signal.
  • Epigenetic aging: reduced epigenetic age in CADASIL mice (Kastberger 2024) invites human epigenetic-clock measurements; absent human confirmation, the longevity rationale stays theoretical.
  • Harms signal: future pooled stroke analyses could confirm or dissolve the non-fatal serious event signal (Ziganshina 2023), shifting the risk balance in either direction.
  • Research integrity: retractions of several Cerebrolysin mouse papers (Rockenstein 2025; Doppler 2026) call for independent replication of the mechanistic literature.

Conclusion

Cerebroprotein hydrolysate is a mixture of small protein fragments and amino acids made from pig brain, given as courses of injections or infusions. It is a prescription medicine in many countries but is not approved in the United States. Its best-supported effects are in people who already have brain or spinal-cord disease: modestly faster early recovery after stroke, small short-term gains in thinking and in doctors’ overall ratings in dementia, and better recovery in some spinal-cord and head-injury settings. Lasting gains in independence after stroke and any survival benefit are not established.

For healthy adults hoping to protect the aging brain, the evidence is thin. Only one small, short trial has tested the injected product in healthy people, a related oral product has only small and indirect support, and the findings on aging and lifespan come from animals only; separately, several mouse studies from one laboratory on how it works have been retracted.

Harms in trials have mostly been mild and similar to placebo, yet an independent review of stroke trials found more non-fatal serious events, a signal a larger analysis did not confirm, and allergic reactions, agitation, low mood and rare seizures are recognized. Much of the evidence was produced or funded by the manufacturer, and several look-alike products appear to lack its biological activity, so the source of the product matters as much as the dose. Overall, the evidence base is large in number of trials but limited in independence, size and relevance to healthy aging.

Top - Benefits - Risks - Protocol